Endogenous opioid peptides play a major role in brain function, and opiate drugs are both clinically important and socially abused. Based on pharmacological and ligand binding studies, receptors for these compounds have been divided into five major classes: mu, delta, kappa, sigma, and epsilon. However, physico-chemical evidence for distinct opiate binding proteins is lacking and thus little is known of the physical and chemical characteristics which differentiate these receptor types. Derivatives of opiate alkaloids and opioid peptides will be synthesized which will irreversibly bind to mu, delta, and kappa receptor types. The derivatives will be analyzed for binding affinity, receptor selectivity, and irreversibility by competition studies with labeled reversible mu, delta, and kappa receptor probes. The tritiated or radioiodinated form of suitable ligands will then be synthesized. Brain membrane homogenates and cryostat-cut, slide-mounted thin sections of brain will be treated with these compounds. Labeled membranes will be solubilized with detergents and the extracts subjected to electrophoretic analysis. Proteins labeled by mu, delta, and kappa receptor probes will be characterized with regards to their molecular weights, isoelectric points, and peptide maps to determine the degree of similarity. Finally, a structural model for the receptor, Type 1 receptor model, will be tested. This model involves interacting mu and delta binding sites either in a protein complex or binding domains on a single polypeptide chain. This will be accomplished by ascertaining the proximity of binding sites to each other in the membrane by analyzing the effect of protein crosslinking reagents on the electrophoretic-mobilities of the labeled receptor proteins. It is anticipated that this approach will lead to chemical identification of the receptor types and will define the molecular basis of opiate receptor heterogeneity. In addition, the irreversibly binding opiate ligands produced in this project may prove useful in pharmacological and behavioral studies of opiate action.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003776-02
Application #
3208411
Study Section
(DABB)
Project Start
1985-06-01
Project End
1988-05-31
Budget Start
1986-06-01
Budget End
1987-05-31
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Brown University
Department
Type
Schools of Medicine
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Hellewell, S B; Bruce, A; Feinstein, G et al. (1994) Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268:9-18
Beczkowska, I W; Bowen, W D; Bodnar, R J (1992) Central opioid receptor subtype antagonists differentially alter sucrose and deprivation-induced water intake in rats. Brain Res 589:291-301
Berson, D M; Graybiel, A M; Bowen, W D et al. (1991) Evidence for intrinsic expression of enkephalin-like immunoreactivity and opioid binding sites in cat superior colliculus. Neuroscience 43:513-29
Arjune, D; Bowen, W D; Bodnar, R J (1991) Ingestive behavior following central [D-Ala2, Leu5, Cys6]-enkephalin (DALCE), a short-acting agonist and long-acting antagonist at the delta opioid receptor. Pharmacol Biochem Behav 39:429-36
Calcagnetti, D J; Bowen, W D; Holtzman, S G (1990) Stress-induced tolerance to delta receptor agonist DPDPE and selectivity of the irreversible delta-ligand, DALCE. Brain Res 509:205-12
Hellewell, S B; Bowen, W D (1990) A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 527:244-53
Calcagnetti, D J; Fanselow, M S; Helmstetter, F J et al. (1989) [D-Ala2,Leu5,Cys6]enkephalin: short-term agonist effects and long-term antagonism at delta opioid receptors. Peptides 10:319-26
Bowen, W D; Hellewell, S B; McGarry, K A (1989) Evidence for a multi-site model of the rat brain sigma receptor. Eur J Pharmacol 163:309-18
de Costa, B R; Bowen, W D; Hellewell, S B et al. (1989) Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands. J Med Chem 32:1996-2002
Bluth, L S; Rice, K C; Jacobson, A E et al. (1989) Acylation of sigma receptors by Metaphit, an isothiocyanate derivative of phencyclidine. Eur J Pharmacol 161:273-7

Showing the most recent 10 out of 17 publications